Vincent R. Anicetti Sells 2,500 Shares of Coherus Biosciences Inc (NASDAQ:CHRS) Stock

Coherus Biosciences Inc (NASDAQ:CHRS) COO Vincent R. Anicetti sold 2,500 shares of the stock in a transaction on Monday, July 15th. The stock was sold at an average price of $19.20, for a total transaction of $48,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Shares of NASDAQ CHRS opened at $18.08 on Friday. The business’s fifty day moving average price is $19.94. Coherus Biosciences Inc has a 1 year low of $8.32 and a 1 year high of $23.43. The stock has a market capitalization of $1.23 billion, a P/E ratio of -5.61 and a beta of 3.12.

Coherus Biosciences (NASDAQ:CHRS) last posted its quarterly earnings data on Thursday, May 9th. The biotechnology company reported ($0.29) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.45) by $0.16. The company had revenue of $37.10 million for the quarter, compared to analysts’ expectations of $36.83 million. On average, analysts forecast that Coherus Biosciences Inc will post -0.45 EPS for the current year.

Several large investors have recently bought and sold shares of CHRS. Legal & General Group Plc lifted its stake in shares of Coherus Biosciences by 12.3% in the fourth quarter. Legal & General Group Plc now owns 9,095 shares of the biotechnology company’s stock worth $82,000 after buying an additional 998 shares in the last quarter. SG Americas Securities LLC acquired a new stake in Coherus Biosciences during the first quarter worth about $108,000. BNP Paribas Arbitrage SA increased its position in Coherus Biosciences by 107,870.0% during the first quarter. BNP Paribas Arbitrage SA now owns 10,797 shares of the biotechnology company’s stock worth $147,000 after purchasing an additional 10,787 shares during the last quarter. Ellis Investment Partners LLC acquired a new stake in Coherus Biosciences during the first quarter worth about $155,000. Finally, Xact Kapitalforvaltning AB acquired a new stake in Coherus Biosciences during the second quarter worth about $225,000. 99.18% of the stock is currently owned by hedge funds and other institutional investors.

A number of analysts recently issued reports on CHRS shares. ValuEngine downgraded shares of Zynerba Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday. BidaskClub downgraded shares of Walgreens Boots Alliance from a “sell” rating to a “strong sell” rating in a report on Monday, June 24th. Zacks Investment Research downgraded shares of Farmland Partners from a “hold” rating to a “sell” rating in a report on Friday, July 12th. HC Wainwright increased their price target on shares of Applied Genetic Technologies from $5.75 to $12.00 and gave the stock a “buy” rating in a report on Tuesday, May 7th. Finally, Maxim Group reissued a “buy” rating and set a $25.00 price target on shares of Coherus Biosciences in a report on Wednesday, July 10th. One investment analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company’s stock. Coherus Biosciences has a consensus rating of “Buy” and an average target price of $29.14.

Coherus Biosciences Company Profile

Coherus BioSciences, Inc, a commercial-stage biotherapeutics company, focuses on the biosimilar market worldwide. It markets UDENYCA, a long-acting granulocyte-colony stimulating factor, which stimulates production of granulocytes in order to promote the body's ability to fight infections. The company sells UDENYCA in the United States.

Read More: Cost of Goods Sold (COGS)

Insider Buying and Selling by Quarter for Coherus Biosciences (NASDAQ:CHRS)

Receive News & Ratings for Coherus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus Biosciences and related companies with's FREE daily email newsletter.